Coverage
— → Added to coverage
Current stock research snapshot · Not reviewed Date unavailable
MRNAModerna
Investment conviction●●●○○3 of 5 · current snapshot
Research target—Current stock price target
Investment thesis statusNEEDS_MORE_DATALast reviewed Not reviewed
Market cap$55.09BSnapshot value · Not reviewed
Research history
See all MRNA changes ↗What changed
mRNA platform with strongest direct personalized neoantigen cancer-vaccine validation. intismeran autogene (V940/mRNA-4157) + pembrolizumab MET Phase 3 primary endpoint (INTerpath-001, resected melanoma, 2026-08-19) — first positive Ph3 for an individualized neoantigen therapy. Product+platform value capture (mRNA manufacturing verticalized). Demand engine, high binary risk.
INTerpath-002/009/014 NSCLC Phase 3 readouts; bladder/RCC expansion; manufacturing COGS reduction for batch-of-one; melanoma regulatory filing.
NSCLC/breadth trials miss; personalized manufacturing COGS stays uneconomic at scale; BioNTech/other platforms out-execute; checkpoint-backbone economics accrue to MRK not MRNA.
No social-sentiment snapshot available.
Snapshot · Not reviewed🟡 Mixed · ins-$35.2M · 13F 18+/6-×0.5 · short↑0.3
Snapshot · Not reviewed